Quick Answer
Bioventus Inc. reported Total Assets of $683.56 million for the year ending 2025.
- Bioventus Inc. showed a decrease of -6.1% in Total Assets from 2024 to 2025.
- This data is from Bioventus Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $643.08 million | Q2 2021: $646.64 million | Q3 2021: $654.79 million | Q1 2022: $1.20 billion | Q2 2022: $1.21 billion | Q3 2022: $1.40 billion | Q1 2023: $887.40 million | Q2 2023: $836.96 million | Q3 2023: $811.10 million | Q1 2024: $794.24 million | Q2 2024: $792.17 million | Q3 2024: $769.49 million | Q1 2025: $691.41 million | Q2 2025: $706.79 million | Q3 2025: $701.59 million.
- Over the full 6 years of available data (2020 to 2025), Bioventus Inc.'s Total Assets has grown by 38.2%.
- Historical annual values: Fiscal year 2025: $683.56 million | Fiscal year 2024: $727.96 million | Fiscal year 2023: $810.91 million | Fiscal year 2022: $1.37 billion | Fiscal year 2021: $1.23 billion | Fiscal year 2020: $494.47 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: